Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (HEPA) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic liver diseases through its proprietary cyclophilin inhibitor platform. This page provides investors and industry stakeholders with timely updates on material developments including clinical trial progress, regulatory milestones, and strategic partnerships.
Our curated news feed delivers essential updates on HEPA's lead candidate CRV431, a pipeline targeting fibrosis, hepatocellular carcinoma, and viral hepatitis. Users will find verified information on Phase 2/3 trial results, FDA communications, and collaborative research initiatives without promotional bias.
The repository includes press releases covering three key areas: clinical development updates detailing patient enrollment and trial outcomes, business strategy announcements regarding licensing agreements, and scientific presentations at hepatology conferences. All content is vetted for material relevance to investment analysis and therapeutic advancement.
Bookmark this page for direct access to Hepion's latest developments in pleiotropic liver disease therapies. Check regularly for updates that may influence long-term valuation assessments in the competitive hepatology therapeutics sector.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that the FDA granted Fast Track designation for its lead drug candidate, CRV431, in treating non-alcoholic steatohepatitis (NASH). This designation enables expedited approval reviews and facilitates early communication with the FDA. CRV431 has shown efficacy in early clinical trials and is set to enter a larger Phase 2b study called ASCEND-NASH. Given that approximately 5% of U.S. adults have NASH and no FDA-approved treatments exist, this designation is significant for advancing CRV431 to market.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced promising nonclinical research results for its lead drug CRV431, which significantly reduced liver tumor growth in a mouse model. The study demonstrated that CRV431 decreased tumor size by 76%, rivaling an anti-PD1 antibody, while a combination treatment further improved outcomes by 83%. Additionally, CRV431 positively altered immune cell populations in tumors, suggesting enhanced anti-cancer activity. These findings support CRV431’s potential for treating hepatocellular carcinoma and non-alcoholic steatohepatitis, addressing urgent medical needs.
Hepion Pharmaceuticals (HEPA) announced that results from its Phase 2a AMBITION NASH trial will be available as an e-poster at the virtual Liver Meeting® 2021 from November 12-15, 2021. The trial, involving 43 patients, focused on CRV431 administration and successfully met all primary endpoints, demonstrating safety and pharmacokinetics. The trial's findings suggest the efficacy of CRV431 for treating NASH. Additionally, Hepion plans to utilize its AI-POWR™ platform to optimize patient response and explore further indications for CRV431.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that a study on its lead drug candidate, CRV431, will be presented as an e-poster at the Liver Meeting® 2021 from November 12-15. The research, led by Dr. Philippe Gallay, demonstrates that cyclophilin D knockout mice showed significantly lower tumor burden scores, suggesting that cyclophilin inhibition could be an effective treatment for hepatocellular carcinoma (HCC) linked to non-alcoholic steatohepatitis (NASH). CRV431, an AI-driven therapeutic, aims to reduce liver disease progression, showing potential in treating NASH.
Hepion Pharmaceuticals (NASDAQ:HEPA), a clinical-stage biopharmaceutical company specializing in AI-driven drug development, announced that its CMO, Dr. Todd Hobbs, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 4:00 p.m. ET. This virtual presentation will be accessible live and archived on the company's website.
The lead drug candidate, CRV431, is in clinical development for the treatment of NASH and aims to improve outcomes in liver disease. Hepion's proprietary platform, AI-POWR™, is designed to identify optimal NASH patient responses.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced results from a Drug-Drug Interaction study of its lead drug candidate, CRV431, which targets cyclophilins to treat non-alcoholic steatohepatitis (NASH). The study showed that CRV431's pharmacokinetics were significantly enhanced when administered with ketoconazole, increasing Cmax five-fold and AUC0-24 nearly four-fold. Importantly, CRV431's interaction with midazolam was minimal, indicating its compatibility with other medications. The findings confirm CRV431's safety profile and potential for treating NASH patients with multiple drug therapies.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced promising results from its Phase 2a AMBITION trial of CRV431, aimed at treating non-alcoholic steatohepatitis (NASH). The trial showed significant reductions in biomarkers Pro-C3 and alanine aminotransferase (ALT), suggesting anti-inflammatory and antifibrotic effects. Advanced AI-POWR™ models indicated accurate predictions of patient responses to treatment. The study's success sets a foundation for the upcoming Phase 2b ASCEND-NASH trial, which aims to further evaluate CRV431's efficacy in NASH patients.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced it will release additional data from its Phase 2a AMBITION NASH clinical trial on September 13, 2021. The trial has already achieved all primary endpoints, and a conference call is scheduled for the same day to discuss the topline results and new data. The company's lead drug candidate, CRV431, is positioned to address non-alcoholic steatohepatitis (NASH) and liver disease. Hepion's proprietary AI platform, AI-POWR™, aims to enhance patient selection and drive clinical development for CRV431 and potentially other indications.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced the postponement of its 2021 Annual Meeting of Stockholders originally scheduled for July 23, 2021, due to a lack of quorum. The Board of Directors will determine a new date and record date for the meeting. Hepion's lead drug candidate, CRV431, is under development for non-alcoholic steatohepatitis (NASH) and has shown promise in reducing liver fibrosis and hepatocellular carcinoma in preclinical studies. The company also introduced AI-POWR™, an AI platform aimed at improving patient response identification for CRV431.
Hepion Pharmaceuticals announced positive topline results from its Phase 2a AMBITION trial of CRV431, targeting non-alcoholic steatohepatitis (NASH). All primary endpoints were met, with no serious adverse events reported, indicating good safety and tolerability. The trial showed significant reductions in serum alanine aminotransferase (ALT) levels, a key NASH biomarker, suggesting a strong dose-response effect. Hepion plans to initiate a Phase 2b trial later in 2021, utilizing insights from the AMBITION trial to enhance CRV431’s development for NASH treatment.
FAQ
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
What is the market cap of Hepion Pharmaceuticals (HEPA)?
